GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (OTCPK:ARUXF) » Definitions » Construction In Progress

Acrux (ARUXF) Construction In Progress : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Acrux Construction In Progress?


Acrux Construction In Progress Historical Data

The historical data trend for Acrux's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Construction In Progress Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acrux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Acrux Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Acrux Business Description

Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.